Making Rare Diseases Count: How Better Data Can Unlock a Multitrillion-Dollar Opportunity

The report highlights that rare diseases affect over 300 million people and incur an annual global cost exceeding $7 trillion, yet 95% lack authorized treatments. It proposes five data-driven strategies: establishing a minimum dataset, strengthening patient engagement, improving newborn screening, enabling trusted data sharing, and utilizing AI. The document emphasizes that rare disease innovation often creates 'spillovers' that benefit general medicine, such as mRNA technology and genomic sequencing.

• Rare diseases have a massive global footprint, affecting more than 300 million patients and impacting over 1 billion people when including families and caregivers. The total annual global economic cost is estimated to exceed $7 trillion.
• There is a critical gap in available treatments, with approximately 95% of rare diseases lacking any therapy authorized by a major regulatory agency.
• The report identifies a 'virtuous cycle' where rare disease investments drive systemic benefits: better data leads to clinical impact and system efficiency, which creates research capital, fueling innovation that then produces 'spillover effects' for common medical conditions.
• Rare disease research has been a primary incubator for frontier medical technologies, including mRNA vaccines, gene therapies, RNA interference (RNAi), and next-generation sequencing platforms now used in oncology and infectious diseases.
• The document proposes a 'minimum dataset' to standardize global data collection, focusing on incidence and burden of disease, access to treatments, and the scale of investments.
• Patient registries are highlighted as essential for innovation; for example, the Foundation for Prader-Willi Research (FPWR) used registry data to support the 2025 FDA approval of DCCR tablets for treating hyperphagia.
• Diagnostic delays impose heavy financial burdens, with one study finding that delays across seven rare conditions resulted in avoidable costs of up to $517,000 per patient.
• The European Health Data Space (EHDS), which entered into force in March 2025, is cited as a model for enabling secure, cross-border access to health data for both primary care and secondary research.
• AI is being used to close evidence gaps, such as Sanofi's OSCAR algorithm, which increased detection efficiency for type 1 diabetes more than 18-fold in initial evaluations and is being adapted for Pompe and Fabry diseases.
• In low- and middle-income countries (LMICs), Egypt is presented as a leader by implementing a digitalized newborn screening programme covering over 90% of neonates and establishing a rare disease law for sustainable funding.
• The Rare Care Centre at Perth Children's Hospital demonstrated a 5:1 return on investment by reducing hospital bed days and emergency department presentations by 33% and 40% respectively through coordinated care.

APA

World Economic Forum (2026). Making Rare Diseases Count: How Better Data Can Unlock a Multitrillion-Dollar Opportunity. https://reports.weforum.org/docs/WEF_Making_Rare_Diseases_Count_2026.pdf

Chicago

World Economic Forum. Making Rare Diseases Count: How Better Data Can Unlock a Multitrillion-Dollar Opportunity. 2026. https://reports.weforum.org/docs/WEF_Making_Rare_Diseases_Count_2026.pdf.

Wikipedia

{{cite report |author=World Economic Forum |title=Making Rare Diseases Count: How Better Data Can Unlock a Multitrillion-Dollar Opportunity |date=February 2026 |url=https://reports.weforum.org/docs/WEF_Making_Rare_Diseases_Count_2026.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{worldeconomicforum2026making, author = {{World Economic Forum}}, title = {{Making Rare Diseases Count: How Better Data Can Unlock a Multitrillion-Dollar Opportunity}}, institution = {World Economic Forum}, year = {2026}, month = feb, url = {https://reports.weforum.org/docs/WEF_Making_Rare_Diseases_Count_2026.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }